These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 33992445)

  • 1. Expanding access to nurse-managed medication for opioid use disorder.
    Cos TA; Starbird LE; Lee H; Chun B; Gonnella K; Bird J; Livsey K; Bastos S; O'Brien M; Clark I; Jenkins D; Tavolaro-Ryley L
    Nurs Outlook; 2021; 69(5):848-855. PubMed ID: 33992445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine prescribing by APRNs.
    Rundio A
    J Addict Nurs; 2012 Feb; 23(1):80-1. PubMed ID: 22468666
    [No Abstract]   [Full Text] [Related]  

  • 3. Advanced Practice Nurses: Increasing Access to Opioid Treatment by Expanding the Pool of Qualified Buprenorphine Prescribers.
    Tierney M; Finnell DS; Naegle MA; LaBelle C; Gordon AJ
    Subst Abus; 2015; 36(4):389-92. PubMed ID: 26587696
    [No Abstract]   [Full Text] [Related]  

  • 4. The prescribing of buprenorphine by advanced practice addictions nurses.
    Strobbe S; Hobbins D
    J Addict Nurs; 2012 Feb; 23(1):82-3. PubMed ID: 22468667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
    Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
    Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and prescribing practices of clinicians recently waivered to prescribe buprenorphine for the treatment of opioid use disorder.
    Jones CM; McCance-Katz EF
    Addiction; 2019 Mar; 114(3):471-482. PubMed ID: 30194876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preliminary results of the evaluation of the California Hub and Spoke Program.
    Darfler K; Sandoval J; Pearce Antonini V; Urada D
    J Subst Abuse Treat; 2020 Jan; 108():26-32. PubMed ID: 31400985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient perceptions of treatment with medication treatment for opioid use disorder (MOUD) in the Vermont hub-and-spoke system.
    Rawson RA; Rieckmann T; Cousins S; McCann M; Pearce R
    Prev Med; 2019 Nov; 128():105785. PubMed ID: 31362002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives on APRN prescribing of medications for opioid use disorder: Key barriers remain.
    Chapman SA; Fraimow-Wong L; Phoenix BJ; Tierney M; Spetz J
    J Subst Use Addict Treat; 2024 Feb; 157():209215. PubMed ID: 37979946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid use disorder and COVID-19: Implications for policy and practice.
    Mitchell M; Shee K; Champlin K; Essary AC; Evans M
    JAAPA; 2021 Jun; 34(6):1-4. PubMed ID: 34031321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of NPs in medication-assisted treatment for opioid use disorder.
    Cotton BP; Ferszt GG
    Nurse Pract; 2018 May; 43(5):8. PubMed ID: 29668514
    [No Abstract]   [Full Text] [Related]  

  • 13. From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado.
    Sorrell TR; Weber M; Alvarez A; Beste N; Hollins U; Amura CR; Cook PF
    J Subst Abuse Treat; 2020 Jul; 114():108027. PubMed ID: 32527514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine Supply, Access, and Quality: Where We Have Come and the Path Forward.
    Breen CT; Fiellin DA
    J Law Med Ethics; 2018 Jun; 46(2):272-278. PubMed ID: 30147002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Washington State Hub and Spoke Model to increase access to medication treatment for opioid use disorders.
    Reif S; Brolin MF; Stewart MT; Fuchs TJ; Speaker E; Mazel SB
    J Subst Abuse Treat; 2020 Jan; 108():33-39. PubMed ID: 31358328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving access to care through Advanced Practice Registered Nurses: Focus on perinatal patients with Opioid Use Disorder.
    Ramage M; Tak C; Goodman D; Johnson E; Barber C; Jones HE
    J Adv Nurs; 2021 Jan; 77(1):4-10. PubMed ID: 32975850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Time Is Now: The Role of Pharmacotherapies in Expanding Treatment for Opioid Use Disorder.
    Gordon AJ; Jenkins JA
    Subst Abus; 2015; 36(2):127-8. PubMed ID: 25826044
    [No Abstract]   [Full Text] [Related]  

  • 18. Deploying science to change hearts and minds: Responding to the opioid crisis.
    Walsh SL; Long KQX
    Prev Med; 2019 Nov; 128():105780. PubMed ID: 31319116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empowering Psychiatric Mental Health Nurse Practitioners to Expand Treatment Opportunities for Veterans With Opioid Use Disorder.
    Jones J; Tierney M; Jacobs G; Chien SY; Mallisham S
    J Addict Nurs; 2020; 31(4):261-268. PubMed ID: 33264198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nurse Practitioner and Physician Assistant Waivers to Prescribe Buprenorphine and State Scope of Practice Restrictions.
    Spetz J; Toretsky C; Chapman S; Phoenix B; Tierney M
    JAMA; 2019 Apr; 321(14):1407-1408. PubMed ID: 30964519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.